Understanding how Trypanosoma cruzi can become dormant and its effects on treatment
Trypanosoma cruzi dormancy and its implications for therapeutic treatment
This study is looking at how the Chagas disease parasite can go into a sleepy state that makes it hard to treat, and by understanding this better, the researchers hope to find new ways to make existing treatments work better for people with Chagas disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Georgia NIH-funded |
| Lab location | 1 site (Athens, United States) |
| Project ID | NIH-10773091 on NIH RePORTER |
What this research studies
This research investigates the dormant state of Trypanosoma cruzi, the parasite responsible for Chagas disease, which allows it to resist treatment with antiparasitic drugs. By studying how this dormancy occurs in different host tissues and over time, the researchers aim to enhance the effectiveness of existing treatments. They will also explore new compounds that can reverse this dormancy, potentially leading to improved therapeutic options for patients. The research employs advanced imaging techniques to identify small molecules that can influence the parasite's life cycle and treatment response.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Chagas disease, particularly those experiencing chronic infections.
Not a fit: Patients who do not have Chagas disease or are not experiencing chronic infections may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for Chagas disease, improving patient outcomes.
How similar studies have performed: Previous research has shown promise in understanding microbial dormancy and its implications for treatment, suggesting that this approach could yield valuable insights.
Where this research is happening
Athens, United States
- University of Georgia — Athens, United States (Active)
Researchers
- Principal investigator: Tarleton, Rick L — University of Georgia
- Study coordinator: Tarleton, Rick L
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.